☆ 4.6 Letter

HEPCIDIN, ANAEMIA, AND PROSTATE CANCER

BJU INTERNATIONAL (2011)

期刊

BJU INTERNATIONAL

卷 107, 期 4, 页码 678-679

出版社

WILEY-BLACKWELL

DOI: 10.1111/j.1464-410X.2011.10108.x

关键词

-

类别

Urology & Nephrology

资金

Intramural NIH HHS [ZIA DK025100-04] Funding Source: Medline

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Medicine, General & Internal

Anaemia of chronic diseases: Pathophysiology, diagnosis and treatment

Ricardo de las Cuevas Allende, Lucia Diaz de Entresotos, Susana Conde Diez

Summary: Anaemia of chronic disease is caused by immune system activation, commonly seen in the elderly and hospitalized patients, impacting quality of life when severe, with treatment aimed at controlling underlying disease and correcting anaemia.

MEDICINA CLINICA (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Ferritin, Hepcidin and Cytokines Link in the Diagnoses of Iron Deficiency Anaemia during Pregnancy: A Review

Yvonne Chibanda, Matthew Brookes, David Churchill, Hafid Al-Hassi

Summary: Iron deficiency anaemia during pregnancy is a common problem in the UK and globally. The current diagnosis and treatment methods need improvement, and there are still many questions regarding the mechanisms of iron metabolism and the significance of inflammatory markers.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Plant Sciences

Possible mechanisms by which silkworm faeces extract ameliorates adenine-induced renal anaemia in rats

Hao Mei, Niuniu Wu, Xiao Huang, Zheng Cui, Jingya Xu, Xiawen Yang, Fang Zeng, Kaiping Wang

Summary: Silkworm faeces extract (SFE) effectively improves renal anaemia by promoting erythropoietin (EPO) synthesis and inhibiting hepcidin expression.

JOURNAL OF ETHNOPHARMACOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?

Lucia Del Vecchio, Roberto Minutolo

Summary: Anemia is a well-known consequence of chronic kidney disease, often treated with a combination of ESA and iron. However, safety concerns have arisen regarding their use, particularly in high doses in certain patient populations. Iron deficiency is common in CKD patients, with potential benefits of intravenous iron therapy in heart failure. Additional treatment options, such as PHD inhibitors and targeting serum hepcidin, are being explored but their clinical impact is still uncertain.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Hematology

Iron parameters in pregnant women with beta-thalassaemia minor combined with iron deficiency anaemia compared to pregnant women with iron deficiency anaemia alone demonstrate the safety of iron supplementation in beta-thalassaemia minor during pregnancy

Niankun Chen, Zhongjun Li, Yingying Huang, Chaoqun Xiao, Xinyang Shen, Shumin Pan, Qiongqiong Su, Zhijian Wang

Summary: This study investigated the iron metabolism in pregnant women with beta-thalassaemia minor and iron deficiency anaemia, finding that hepcidin functions normally in maintaining iron balance and that iron supplementation is effective and safe in improving their condition. Additionally, there was no significant correlation between hepcidin and GDF15, but a positive correlation was observed between hepcidin and ferritin levels.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Week-One Anaemia was Associated with Increased One-Year Mortality in Critically Ill Surgical Patients

Feng-Hsu Wu, Li-Ting Wong, Chieh-Liang Wu, Wen-Cheng Chao

Summary: This study investigated the association between anaemia and one-year mortality in critically ill surgical patients in ICUs, and found that anaemia was independently associated with an increased risk of one-year mortality.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2022)

添加到收藏夹

Article Hematology

A simplified diagnostic pathway for the differential diagnosis of iron deficiency anaemia and anaemia of chronic disease

Nicola Svenson, James Bailey, Senthilkumar Durairaj, Nina Dempsey-Hibbert

Summary: This study investigated the potential of using hepcidin in conjunction with reticulocyte haemoglobin equivalent (RetHe) to differentiate between iron deficiency anaemia (IDA) and anaemia of chronic disease (ACD), as well as exclude IDA in patients with mixed aetiology. The results showed that hepcidin, along with RetHe, offers a new simplified diagnostic pathway for differential diagnosis of IDA and ACD, reducing the diagnostic turnaround time and allowing appropriate treatment of patients with true iron deficiency.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Cancer: The role of iron and ferroptosis

Gautam Rishi, Gary Huang, V. Nathan Subramaniam

Summary: Iron is essential for all living organisms and its levels are tightly controlled. Increased iron levels are associated with poor prognosis in cancer, making understanding the role of iron in cancer crucial. Ferroptosis, a new form of iron-regulated cell death triggered by increased iron levels and peroxidation of lipids, may have a role in the treatment of cancers.

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2021)

添加到收藏夹

Review Oncology

Distinctive modulation of hepcidin in cancer and its therapeutic relevance

Feng Lin, Alex Tuffour, Guijie Hao, Frank Addai Peprah, Aixia Huang, Yang Zhou, Haiqi Zhang

Summary: Hepcidin is a crucial iron-regulating factor that regulates intestinal iron absorption and releases iron from macrophages into plasma. Tumor and non-tumor cells express and control hepcidin differently, and studying these variations could lead to potential novel cancer treatments.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Review Medicine, General & Internal

Prostate cancer

Shahneen Sandhu, Caroline M. Moore, Edmund Chiong, Himisha Beltran, Robert G. Bristow, Scott G. Williams

Summary: Management of prostate cancer is rapidly evolving with advances in understanding the genomic landscape, improved imaging methods, and personalised therapeutics targeting DNA repair pathways. The therapeutic framework for metastatic disease has shifted, with oligometastatic disease being evaluated for metastatic-directed therapies, and novel androgen pathway inhibitors showing significant survival benefits as first-line therapy for metastatic disease. Emerging research into molecular characterisation and novel therapeutics, such as targeted radioisotopes and immunotherapy, hold promise for improving patient outcomes.

LANCET (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Iron and liver cancer: an inseparable connection

Keisuke Hino, Izumi Yanatori, Yuichi Hara, Sohji Nishina

Summary: Iron is essential for organisms, playing critical roles in cellular functions. However, excess iron can cause damage to cells and cellular DNA. Most excess iron is stored in the liver, and liver diseases such as haemochromatosis are associated with a higher risk of liver cancer. Studies have shown that iron plays important roles in the development of liver cancer.

FEBS JOURNAL (2022)

添加到收藏夹

Editorial Material Hematology

Erythroferrone in iron regulation and beyond

Jodie L. Babitt

Summary: In this study, a new mouse model overexpressing ERFE, a regulator of erythroid hepcidin, was generated. The results show that increased levels of ERFE not only suppress hepcidin and load iron, but also impact the development and homeostasis of several organ systems.

BLOOD (2022)

添加到收藏夹

Review Genetics & Heredity

Fanconi Anaemia, Childhood Cancer and the BRCA Genes

Emma R. Woodward, Stefan Meyer

Summary: Fanconi anaemia is a hereditary chromosomal instability disorder caused by pathogenic variants in BRCA2 and BRCA1 genes, which are strongly associated with specific types of cancers and may also play a role in non-syndromic cancer predisposition in children.

GENES (2021)

添加到收藏夹

Review Nutrition & Dietetics

Cancer Related Anemia: An Integrated Multitarget Approach and Lifestyle Interventions

Valentina Natalucci, Edy Virgili, Federica Calcagnoli, Giacomo Valli, Deborah Agostini, Sabrina Donati Zeppa, Elena Barbieri, Rita Emili

Summary: Cancer-related anemia (CRA) is often linked to worsened iron profiles in patients, impacting treatment efficacy and survival. Challenges in therapy lie in the relationship between anemia and inflammatory status, with a suggested approach involving nutrition, exercise, and antioxidant support for a comprehensive treatment plan.

NUTRIENTS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants

Demitria M. Vasilatis, Christopher A. Lucchesi, Paramita M. Ghosh

Summary: Dogs naturally develop prostate cancer similar to aggressive forms found in humans. Prostate cancer samples in dogs often lack androgen receptor (AR), which can enhance our understanding of AR-indifferent prostate cancer in humans. This review highlights the molecular similarities between dog and human prostate cancer variants, suggesting the potential use of dogs as pre-clinical animal models for developing new therapies and diagnostics that can benefit both species.

BIOMEDICINES (2023)

添加到收藏夹

Article Oncology

A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)

Marijo Bilusic, Nicole J. Toney, Renee N. Donahue, Susan Wroblewski, Matthew Zibelman, Pooja Ghatalia, Eric A. Ross, Fatima Karzai, Ravi A. Madan, William L. Dahut, James L. Gulley, Jeffrey Schlom, Elizabeth R. Plimack, Daniel M. Geynisman

Summary: This study investigated the effects of metformin in prostate cancer treatment through a phase 2 trial. The results showed that metformin monotherapy induced modest declines in serum PSA levels in some patients and had an impact on immune cell subsets. However, the combination of metformin and bicalutamide did not improve the rate of achieving undetectable PSA at 32 weeks.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

添加到收藏夹

Article Oncology

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

Meghali Goswami, Gege Gui, Laura W. Dillon, Katherine E. Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y. Ghannam, Karolyn A. Oetjen, Christin B. Destefano, Dana M. Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L. Marte, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L. Gulley, Katherine R. Calvo, Catherine Lai, Christopher S. Hourigan

Summary: This study aimed to investigate the feasibility and efficacy of the combination of PD-1 blockade and hypomethylating therapy in patients with R-AML. The results showed that this combination therapy achieved disease stability or better response in some patients. Moreover, clonal T cell expansions and immunological changes were observed during treatment, which may be associated with treatment-related adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer

Arun Rajan, Jhanelle E. Gray, Siddhartha Devarakonda, Ruemu Birhiray, Borys Korchin, Erika Menius, Renee N. Donahue, Jeffrey Schlom, James L. Gulley

Summary: CV301 in combination with PD-1 inhibitors is safe and clinically active in advanced NSCLC patients, without an increased frequency or severity of immune-related adverse events.

INTERNATIONAL JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies

Diana C. Lopez, Yvette L. Robbins, Joshua T. Kowalczyk, Wiem Lassoued, James L. Gulley, Markku M. Miettinen, Gary L. Gallia, Clint T. Allen, James W. Hodge, Nyall R. London Jr

Summary: This study comprehensively evaluates the tumor immune microenvironment (TIME) of chordoma using multispectral immunofluorescence (MIF). The results show that myeloid cells significantly infiltrate chordoma tumor parenchyma, while T cells tend to be excluded from the tumor parenchyma and have higher stromal infiltration. This suggests that future immunotherapy strategies for chordoma should aim to decrease myeloid cell suppressive function and enhance cytotoxic T cell and NK cell killing.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Molecular Pathways and Mechanisms of TGFb in Cancer Therapy

Mary Helen Barcellos-Hoff, James L. Gulley

Summary: Despite the increasing number of TGFI3 inhibitors tested in cancer patients, there has been no clinical benefit achieved yet. The main obstacle to effective TGFI3 inhibition is the diverse mechanisms by which TGFI3 promotes tumor growth. TGFI3 is involved in regulating DNA repair and immune suppression, which can be used to synergize genotoxic therapy and immunotherapy for the benefit of cancer patients.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation

Cody J. Peer, Keith T. Schmidt, Oluwatobi Arisa, William J. Richardson, Koosha Paydary, Daniel A. Goldstein, James L. Gulley, William D. Figg, Mark J. Ratain

Summary: Atezolizumab, a humanized monoclonal antibody against PD-L1, was approved in 2016. Standard dose regimens result in high plasma concentrations, indicating the need for alternative dosing strategies to reduce exposure burden.

JOURNAL OF CLINICAL PHARMACOLOGY (2023)

添加到收藏夹

Article Oncology

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

Alexander Spira, Michael S. Wertheim, Edward J. Kim, Benjamin Tan, Heinz-Josef Lenz, Petros Nikolinakos, Patricia L. Rich, Genevieve Jehl, Andreas Machl, Rena Ito, James L. Gulley, Scott Kopetz

Summary: A phase I study on bintrafusp alfa in heavily pretreated patients with colorectal cancer showed promising early signs of clinical efficacy and manageable safety profile.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors

Fabrice Barlesi, Nicolas Isambert, Enriqueta Felip, Byoung Chul Cho, Dae Ho Lee, Julio Peguero, Guy Jerusalem, Nicolas Penel, Esma Saada-Bouzid, Pilar Garrido, Christoph Helwig, George Locke, Laureen S. Ojalvo, James L. Gulley

Summary: Bintrafusp alfa showed some clinical activity and a manageable safety profile in heavily pretreated NSCLC patients.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors

Margaret E. Gatti-Mays, Nicholas P. Tschernia, Julius Strauss, Ravi A. Madan, Fatima H. Karzai, Marijo Bilusic, Jason Redman, Houssein Abdul Sater, Charalampos S. Floudas, Nicole J. Toney, Renee N. Donahue, Caroline Jochems, Jennifer L. Marte, Deneise Francis, Sheri McMahon, Elizabeth Lamping, Lisa Cordes, Jeffrey Schlom, James L. Gulley

Summary: The results of this study showed that biweekly NHS-IL12 treatment was safe for patients with advanced cancers. NHS-IL12 is a first-in-class fusion protein used in this trial. Patients received NHS-IL12 every two weeks, and the results demonstrated stable disease status for the patients.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Emerson A. Lim, Michael T. Schweizer, Kim N. Chi, Rahul Aggarwal, Neeraj Agarwal, James Gulley, Edward Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffredo, Nibedita Bandyopadhyay, Hong Xie, Aaron R. Hansen

Summary: PSMA expression is maintained in all stages of prostate cancer. In a phase 1 study, a bispecific antibody targeting PSMA-expressing tumor cells and CD3-expressing T cells showed manageable cytokine release syndrome and temporary decline in PSA in patients with metastatic castration-resistant prostate cancer. Treatment-related deaths and radiographic responses were not observed. PSMA is a potential therapeutic target for T-cell redirection in prostate cancer.

CLINICAL GENITOURINARY CANCER (2023)

添加到收藏夹

Article Oncology

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

Michael B. Atkins, Paolo A. Ascierto, David Feltquate, James L. Gulley, Douglas B. Johnson, Nikhil Khushalani, Jeffrey Sosman, Timonthy A. Yap, Harriet Kluger, Ryan J. Sullivan, Hussein Tawbi

Summary: Immunotherapy alone does not work for all tumors, so combining it with signal transduction inhibitors, such as antiangiogenic therapies, can enhance its effectiveness. Combination therapies with immunotherapy have shown improved antitumor activity in various solid tumor settings and have received regulatory approval for the treatment of several types of cancer. However, many patients still experience progression after combination treatment, highlighting the need for new strategies to address resistance to immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Review Oncology

Vaccinating against cancer: getting to prime time

Ryan Chang, James L. Gulley, Lawrence Fong

Summary: Immunotherapies, such as immune checkpoint inhibitors and cellular therapies, have revolutionized cancer treatment, but the development of successful cancer vaccines remains challenging. Only two vaccines have shown improved survival in advanced disease: sipuleucel-T and talimogene laherparepvec, which target specific antigens and utilize tumors in situ to prime responses. In this review, we examine the challenges and opportunities in developing therapeutic cancer vaccines.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

添加到收藏夹

Meeting Abstract Oncology

Identification of markers for tumor- and immune-derived extracellular vesicles (EVs) in preclinical models

Dove-Anna Johnson, Michelle Pleet, Joshua Aden Welsh, Sean Cook, Jason Savage, Nooshin Mirza Nasiri, Kevin A. Camphausen, Kenneth D. Aldape, James L. Gulley, Beverly A. Mock, Jay A. Berzofsky, Steve Jacobson, Jennifer C. Jones

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Mohammad O. Atiq, Shruti U. Gandhy, Fatima Karzai, Munjid Al Harthy, Gang Chen, Marijo Bilusic, David James VanderWeele, Elias Bin Aris Chandran, Lisa M. Cordes, Helen Owens, Anna Couvillon, Amy Hankin, Monique Williams, William Douglas Figg, Peter L. Choyke, Liza Lindenberg, Esther Mena, William L. Dahut, James L. Gulley, Ravi Amrit Madan

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.

Mohammad O. Atiq, Elias Bin Aris Chandran, Luke Meininger, Fatima Karzai, Marijo Bilusic, Jennifer L. Marte, Philip M. Arlen, Lisa M. Cordes, Julius Strauss, Jason Redman, Charalampos S. Floudas, Danielle M. Pastor, Helen Owens, Amy Hankin, Monique Williams, William Douglas Figg, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi Amrit Madan

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.